Researchers have shown that cancer immunotherapy targeting the tumor biomarker epithelial cell adhesion molecule (EpCAM) is safe and non-toxic in mice and can significantly delay tumor formation and growth. EpCAM is over-expressed ...
Mar 28, 2019
0
1
Experimenting with mice, Johns Hopkins researchers report they have successfully used positron emission tomography (PET) scans to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of ...
Mar 27, 2019
0
6
Cutting-edge sequencing technology has revolutionized cancer diagnosis and since identified several so-called cancer driver genomic aberrations. This has led to the development of an extensive and powerful arsenal of anti-cancer ...
Mar 20, 2019
0
27
Patients living with an aggressive form of lymphoma in Scotland will not get routine access to a new immunotherapy treatment after it was rejected for use on the NHS.
Mar 14, 2019
0
3
(HealthDay)—The U.S. Food and Drug Administration has given its blessing to the first immunotherapy regimen for breast cancer.
Mar 12, 2019
0
54
Among melanoma patients treated with anti-PD-1 immunotherapy, consumption of a high-fiber diet was associated with higher gut microbiome diversity and better response to treatment, according to data presented during a media ...
Feb 28, 2019
0
9
Immune cells called T cells are key components in the fight against cancer. However, they sometimes struggle to recognize cancerous cells or to launch an appropriate response against them. T cell activity can be tweaked to ...
Feb 22, 2019
0
16
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain ...
Feb 20, 2019
0
423
Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins and the Johns Hopkins University School of Medicine report two new forms of an older anti-cancer agent they developed appear to enhance ...
Feb 19, 2019
0
43
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair (DDR) achieved significant tumor ...
Feb 18, 2019
0
14
